SCHEMBL272173

SCHEMBL272173

CN[C@H]1C[C@@H]2OC3(c4cccc5c6c7c(c8c9ccccc9n2c8c6n3c45)C(=O)NC7)[C@H]1OC

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 13/20 0.75
PRKCZ Q05513 9/20 0.75
PRKD3 O94806 8/20 0.75
PRKCG P05129 8/20 0.75
PRKCD Q05655 8/20 0.75
ROCK2 O75116 7/20 0.75
PRKCB P05771 7/20 0.75
PRKCA P17252 7/20 0.75
PRKCH P24723 7/20 0.75
PRKCI P41743 7/20 0.75
PRKCE Q02156 7/20 0.75
PRKD1 Q15139 7/20 0.75
EGFR P00533 5/20 0.75
PRKACA P17612 5/20 0.75
KDR P35968 4/20 0.75
SRC P12931 4/20 0.75
PRKACG P22612 4/20 0.75
PRKACB P22694 4/20 0.75
CHEK1 O14757 3/20 0.75
MAPK1 P28482 3/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14045541 1.00 PRKCQ (0.75) PRKCQPRKCZPRKD3PRKCGPRKCD
SCHEMBL19492755 1.00 PRKCQ (0.75) PRKCQPRKCZPRKD3PRKCGPRKCD
Staurosporine SCHEMBL14264595 0.86 PRKCQ (1.00) PRKCQPRKCZPRKD3PRKCGPRKCD
Staurosporine SCHEMBL17397398 0.86 PRKCQ (1.00) PRKCQPRKCZPRKD3PRKCGPRKCD
Staurosporine SCHEMBL8157 0.86 PRKCQ (1.00) PRKCQPRKCZPRKD3PRKCGPRKCD
Staurosporine SCHEMBL23768489 0.86 PRKCQ (1.00) PRKCQPRKCZPRKD3PRKCGPRKCD
Staurosporine SCHEMBL23793206 0.86 PRKCQ (1.00) PRKCQPRKCZPRKD3PRKCGPRKCD
SCHEMBL24393902 0.86 PRKCQ (1.00) PRKCQPRKCZPRKD3PRKCGPRKCD
Staurosporine SCHEMBL21312855 0.86 PRKCQ (1.00) PRKCQPRKCZPRKD3PRKCGPRKCD
Staurosporine SCHEMBL13659665 0.86 PRKCQ (1.00) PRKCQPRKCZPRKD3PRKCGPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9795389-B2 Embolic coils and related components, systems, and methods BOSTON SCIENTIFIC SCIMED, INC. (US) 2017-10-24 US disclosed
US-7858183-B2 increase in internal pressure eventually causes particle to burst (particle containing a gas generator e.g. water or saline), forming burst particle, and it releases ferromagnetic particles to deliver to unhealthyl tissue; drug delivery system BOSTON SCIENTIFIC SCIMED, INC. (US) 2010-12-28 US disclosed
US-20100198210-A1 PARTICLES BOSTON SCIENTIFIC SCIMED, INC. (US) 2010-08-05 US disclosed
EP-2131754-B1 DEPLOYING EMBOLIC COILS BOSTON SCIENT SCIMED INC (US) 2010-06-02 EP disclosed
US-20070142560-A1 Block copolymer particles BOSTON SCIENTIFIC SCIMED, INC. 2007-06-21 US disclosed
US-20070141340-A1 Block copolymer particles BOSTON SCIENTIFIC SCIMED, INC. 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100198210-A1 PARTICLES APOB, HDLBP, NASP PRKCQ 3002/4885PRKCZ 2746/4885PRKD3 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.